Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | UBE2M | P61081 | 6/20 | 0.47 |
| ▸ | DCUN1D1 | Q96GG9 | 6/20 | 0.47 |
| ▸ | LTA4H | P09960 | 3/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.40 |
| ▸ | ATG4B | Q9Y4P1 | 1/20 | 0.40 |
| ▸ | FLT3 | P36888 | 1/20 | 0.40 |
| ▸ | FAAH | O00519 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4245557 | 0.95 | UBE2M (0.48) | UBE2MDCUN1D1MAPTEPHX2ALDH1A1 | |
| SCHEMBL4236028 | 0.83 | ALDH1A1 (0.47) | UBE2MDCUN1D1MAPTALDH1A1SMN1; SMN2 | |
| SCHEMBL4240045 | 0.83 | ALDH1A1 (0.47) | UBE2MDCUN1D1MAPTALDH1A1SMN1; SMN2 | |
| SCHEMBL4244937 | 0.80 | CCR5 (0.52) | — | |
| SCHEMBL4242742 | 0.79 | UBE2M (0.46) | UBE2MDCUN1D1EPHX2 | |
| SCHEMBL4238870 | 0.79 | MAPT (0.56) | MAPTALDH1A1LMNA | |
| SCHEMBL4241138 | 0.77 | CCR5 (0.64) | UBE2MDCUN1D1 | |
| SCHEMBL4247943 | 0.76 | POLB (0.56) | UBE2MDCUN1D1 | |
| SCHEMBL4238740 | 0.76 | UBE2M (0.41) | UBE2MDCUN1D1MAPTEPHX2ALDH1A1 | |
| SCHEMBL4244424 | 0.74 | ALDH1A1 (0.37) | UBE2MDCUN1D1MAPTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7491735-B2 | Chemokine receptor binding compounds | GENZYME CORPORATION (US) | 2009-02-17 | — | — | US | disclosed |
| US-20050277670-A1 | Chemokine receptor binding compounds | ANORMED INC. | 2005-12-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050277670-A1 | Chemokine receptor binding compounds | CCR5, CXCR3, CCL5 | UBE2M 4562/4885DCUN1D1 3581/4885LTA4H 596/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.